DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-825/SLR-006

Pfizer, Inc.
Attention: Lana Liem-McDonnell
Director
235 E. 42nd Street
New York, NY 10017

Dear Ms. McDonnell:

Please refer to your supplemental new drug application dated October 9, 2001, received October 10, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Geodon (ziprasidone) Capsules.

We acknowledge receipt of your submissions of November 9, 2001, January 3, 2002 and January 29, 2002.

This supplemental new drug application provides for labeling changes in the **CONTRAINDICATIONS** and **WARNINGS** sections of the product labeling and for changes in the **Who should NOT take GEODON** section of the Patient Package Insert (see attached - changes in underline and strikeout font).

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, text for the patient package insert).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-825/SLR-006." Approval of this submission by FDA is not required before the labeling is used.

When the letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane

Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Steven D. Hardeman, R.Ph., Senior Regulatory Project Manager, at (301) 594-5525.

Sincerely,

{See appended electronic signature page}

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Attachments (3)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Russell Katz
2/15/02 10:43:45 AM